Glen Clova Scientific has closed a £4M Seed round, led by Norcliffe Capital. The funding will be used to advance preclinical development of three initial drugs for the treatment of senile pruritus, atopic dermatitis, eczema, and asthma, as well as to exploit its technology platform in non-pharmaceutical markets through partnerships.

Scottish Enterprise

Tricapital Angels

Dsw Ventures

Norcliffe Capital

Scottish biotech startup Glen Clova Scientific is developing drugs for chronic inflammatory and autoimmune disorders. It was founded in 2022 as a spin out from the University of Dundee.

Glen Clova Scientific raises £4M in a Seed round led by Norcliffe Capital to develop drugs for autoimmune diseases

Investors

Description

Company Information

Related People

Funding Insights

Glen Clova Scientific raises £4M in a Seed round led by Norcliffe Capital to develop drugs for autoimmune diseases

Investors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information